Active Ingredient(s): Atezolizumab
FDA Approved: * May 18, 2016
Pharm Company: * GENENTECH INC
Category: Cancer

Atezolizumab, sold under the brand name Tecentriq, is a monoclonal antibody medication used to treat urothelial carcinoma, non-small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), small cell lung cancer (SCLC), and hepatocellular carcinoma (HCC).[2] It is a fully humanized, engineered monoclonal antibody of IgG1 isotype against the protein programmed cell death-ligand 1 (PD-L1).[4] The most common side effects when used on its own include tired... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.

Dosage List

Tecentriq 1200 mg/20ml Intravenous Injection, Solution
NDC: 50242-917
Genentech, Inc.
Tecentriq 840 mg/14ml Intravenous Injection, Solution
NDC: 50242-918
Genentech, Inc.